Drug discovery

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.

Featured

News & Views | 20 June 2022

Targeting drug-resistant mutations in ALK
- Liu He
- & Arvin C. Dar
Nature Cancer 3, 659-661
News & Views | 13 June 2022

Efficacy of antiangiogenic medication to treat arteriovenous malformations

Nature Cardiovascular Research 1, 552-553
News & Views | 02 June 2022

AI-powered aptamer generation
- Majid Khabbazian
- & Hosna Jabbari
Nature Computational Science 2, 356-357

Latest Research and Reviews

Reviews | 25 June 2022

Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition
- Pranav Gupta
- , Hongling Zhao
- & Edward L. Schwartz
British Journal of Cancer, 1-7
Research
25 June 2022 | Open Access

Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation

There is an urgent need for novel strategies to combat life-threatening fungal infections. Here, Revie et al. identify a compound that induces alterations in fungal membranes, synergizes with azole antifungals against the pathogen Candida albicans, and inhibits virulence traits and biofilm formation in animal models of infection.
- Nicole M. Revie
- , Kali R. Iyer
- & Leah E. Cowen
Nature Communications 13, 3634
Research
24 June 2022 | Open Access

A potent estrogen receptor and microtubule specific purine-benzothiazole-based fluorescent molecular probe induces apoptotic death of breast cancer cells
- Surajit Barman
- , Subhajit Ghosh
- & Surajit Ghosh
Scientific Reports 12, 10772
Research
24 June 2022 | Open Access

CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity
- Liliang Li
- , Pan Gao
- & Li Jin
Signal Transduction and Targeted Therapy 7, 190
Research
24 June 2022 | Open Access

Antiprotozoal activity of different Xenorhabdus and Photorhabdus bacterial secondary metabolites and identification of bioactive compounds using the easyPACId approach
- Sebnem Hazal Gulsen
- , Evren Tileklioglu
- & Selcuk Hazir
Scientific Reports 12, 10779
Reviews
23 June 2022 | Open Access

Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target
- Chuanjun Zhuo
- , Feifei Zhao
- & Xueqin Song
Translational Psychiatry 12, 260

All Research & Reviews

News and Comment

Correspondence | 22 June 2022

The show must go on. Reply to “Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al” by Insop Shim
- Jordi Bonaventura
- , Sherry Lam
- & Michael Michaelides
Molecular Psychiatry, 1-2
News & Views | 20 June 2022

Targeting drug-resistant mutations in ALK

Therapy resistance limits the clinical success of tyrosine kinase inhibitors (TKIs) in ALK-positive non-small cell lung cancer. A study now proposes a framework to identify compound resistance mutations to the lorlatinib TKI and provides structure-based drug design approaches to overcome resistance mediated by ALK(G1202R) or ALK(I1171N/S/T).
- Liu He
- & Arvin C. Dar
Nature Cancer 3, 659-661
News & Views | 13 June 2022

Efficacy of antiangiogenic medication to treat arteriovenous malformations

In a prospective experimental observational study of 18 individuals with severe, recurrent extracranial arteriovenous malformations, thalidomide was effective in reducing pain, healing ulceration, stopping bleeding and resolving cardiac failure.

Nature Cardiovascular Research 1, 552-553
News | 13 June 2022

New COVID drugs face delays as trials grow more difficult

Fewer people are eligible for the massive studies needed to test treatments for severe COVID-19.
- Saima May Sidik
Nature 606, 637
Research Highlights | 09 June 2022

Vaccine exposes tumours to immune cell attack
- M. Teresa Villanueva
Nature Reviews Drug Discovery
Research Highlights
04 June 2022 | Open Access

Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects
- Longlong Liu
- , Pradeep Kumar Patnana
- & Subbaiah Chary Nimmagadda
Signal Transduction and Targeted Therapy 7, 178

All News & Comment

Drug discovery

Featured

Targeting drug-resistant mutations in ALK

Efficacy of antiangiogenic medication to treat arteriovenous malformations

AI-powered aptamer generation

Latest Research and Reviews

Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition

Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation

A potent estrogen receptor and microtubule specific purine-benzothiazole-based fluorescent molecular probe induces apoptotic death of breast cancer cells

CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity

Antiprotozoal activity of different Xenorhabdus and Photorhabdus bacterial secondary metabolites and identification of bioactive compounds using the easyPACId approach

Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target

News and Comment

The show must go on. Reply to “Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al” by Insop Shim

Targeting drug-resistant mutations in ALK

Efficacy of antiangiogenic medication to treat arteriovenous malformations

New COVID drugs face delays as trials grow more difficult

Vaccine exposes tumours to immune cell attack

Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects

Quick links

Discover content

Publishing policies

Author & Researcher services

Libraries & institutions

Advertising & partnerships

Career development

Regional websites

Legal & Privacy

Drug discovery

Featured

Related Subjects

Latest Research and Reviews

News and Comment

Search

Quick links